Banno, Koji

写真a

Affiliation

School of Medicine, Department of Obstetrics and Gynecology (Gynecology) （Shinanomachi）

Position

Associate Professor

External Links
Page Top ▲

Career 【 Display / hide 】

  • 1992.05
    -
    1993.05

    慶應義塾大学病院研修医

  • 1995.07
    -
    1996.03

    慶應義塾大学助手(医学部産婦人科学）

  • 1996.04
    -
    2000.03

    癌研究会癌研究所細胞生物部研究生

  • 2001.06
    -
    2005.03

    慶應義塾大学助手（医学部産婦人科学）

  • 2005.04
    -
    2007.03

    慶應義塾大学助手（医学部産婦人科学・外来医長）

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 1992

    Keio University, Faculty of Medicine

    University, Graduated

  • 2000

    Keio University, Graduate School, Division of Medicine, 婦人科腫瘍学・細胞生物学

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, Keio University, Coursework

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 日本臨床細胞学会　指導医

  • 日本婦人科腫瘍学会　専門医

  • がん治療暫定教育医

  • がん治療認定医

  • 日本婦人科腫瘍学会指導医

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Medical biochemistry

  • Life Science / Obstetrics and gynecology

Page Top ▲

Research Keywords 【 Display / hide 】

  • エピジェネテイクス

  • 子宮体癌

  • 子宮内膜

  • 子宮移植

  • 家族性腫瘍

Page Top ▲
 

Books 【 Display / hide 】

  • 今日の治療指針 2023.

    阪埜浩司, 医学書院, 2023.01,  Page： 1317

    Scope: 月経の人口移動法,  Contact page： 230 , Accepted

  • 産科婦人科疾患最新の治療 2022-2024.

    的場優介、阪埜浩司、青木大輔, 南江堂, 2021.12,  Page： 230

    Scope: 子宮内膜増殖症,  Contact page： 230

  • 婦人科腫瘍治療アップデート.

    安達将隆、阪埜浩司、青木大輔., 中外医学社, 2020.09

    Scope: Lynch症候群,  Contact page： 220−231

  • Nonhuman Primate Research in Uterus Transplantation.

    Kisu I, Banno K, Matoba Y, Aoki D. , Splinger, 2020.01

    Scope: Nonhuman Primate Research in Uterus Transplantation.,  Contact page： 57-67

    　View Summary

    Uterus transplantation (UTx) is considered to be a possible approach for women with uterine factor infertility. Clinical research on this procedure has begun in several countries, but UTx is still at the experimental stage and many medical and technical issues remain to be resolved. UTx studies have been performed in many animal species, but further basic studies in animals are needed for accumulation of data that will allow further establishment of UTx, as a safe procedure in humans. In particular, validation using nonhuman primates that are physiologically and anatomically similar to humans is important for extrapolation to humans. In this chapter, the current status of research on UTx in nonhuman primates is summarized.

  • Clinical management of epithelial ovarian cancer

    Kobayashi Y., Nomura H., Kataoka F., Tominaga E., Banno K., Aoki D., Cell Biology of the Ovary: Stem Cells, Development, Cancer, and Clinical Aspects, 2018.06

    　View Summary

    Ovarian cancer has high morbidity and mortality worldwide, and its mortality is the highest among female genital cancers. Improvement in clinical outcome is an urgent issue for ovarian cancer, and clinical management including treatment has been repeatedly studied. Tumor markers such as CA125, CA19-9, and HE4 and image diagnosis using MRI, CT, PET, etc. are indispensable diagnostic aid tools. In the initial treatment, primary debulking surgery (PDS) is basically effective, but fertility preservation can be considered depending on the case. For advanced cancers, interval debulking surgery (IDS) is considered after several cycles of neoadjuvant chemotherapy (NAC). Although the combination of paclitaxel and carboplatin (TC) regimen was originally established as the standard chemotherapy for ovarian cancer regardless of tissue type, new treatments in clinical trials, including molecular-targeted therapeutic agents, are being investigated. The main treatment for recurrent cancer is chemotherapy, and sensitivity to chemotherapy based on the disease-free interval has been considered in the choice of treatment. Furthermore, in recent years, risk-reducing bilateral salpingo-oophorectomy has been undertaken to prevent the onset of hereditary breast and ovarian cancer. It is also being studied how to manage the follow-up after treatment and hormone replacement.

display all >>

Page Top ▲

Papers 【 Display / hide 】

  • 子宮内膜異型増殖症の術前診断で腹腔鏡下手術を施行した症例の検討.

    平田 桃、坂井健良、山上 亘、北澤晶子、家谷佳那、高橋未央、吉村拓馬、吉浜智子、千代田達幸、阪埜浩司、田中 守、青木大輔.

    東京産科婦人科学会誌 72 （ 2 ） 177 - 186 2023.04

    Research paper (scientific journal), Accepted

  • Graft Failure after Uterus Transplantation in 16 Recipients: A Review

    Kisu I., Matsuda R., Shiraishi T., Hayashi R., Matoba Y., Tamate M., Banno K.

    Journal of Clinical Medicine （Journal of Clinical Medicine)  12 （ 5 ）  2023.03

    　View Summary

    Uterus transplantation (UTx) is now an alternative to surrogacy and adoption for women with uterine factor infertility to have children; however, there are still unresolved clinical and technical issues. One of these is that the graft failure rate after transplantation is somewhat higher than that of other life-saving organ transplants, which is a critical concern. Herein, we summarize the details of 16 graft failures after UTx with living or deceased donors using the published literature in order to learn from these negative outcomes. To date, the main causes of graft failure are vascular factors (arterial and/or venous thrombosis, atherosclerosis, and poor perfusion). Many recipients with thrombosis develop graft failure within one month of surgery. Therefore, it is necessary to devise a safe and stable surgical technique with higher success rates for further development in the UTx field.

  • Clinical utility of MR spectroscopy for gynecologic pekvic abscesses using next-generation sequencing technology for the detection of causative bacteria.

    Nogami Y, Banno K, Kobayashi Y, Tominaga E, Okuda S, Aoki D

    （Experimental and Therapeutic Medicine)  25 （ 2 ） 96 2023.01

    Joint Work, Corresponding author, Accepted

  • Case Series of Mayer–Rokitansky–Küster–Hauser Syndrome: Analysis of 17 Cases

    Miyake A., Kobayashi Y., Imaeda K., Yoshihama T., Nakamura K., Yokota M., Hayashi S., Yamagami W., Banno K., Aoki D.

    Clinical and Experimental Obstetrics and Gynecology （Clinical and Experimental Obstetrics and Gynecology)  50 （ 1 ）  2023.01

    ISSN  03906663

    　View Summary

    Background: The Mayer–Rokitansky–Küster–Hauser (MRKH) syndrome is a rare disorder characterized by congenital vaginal defects and uterine traces. Because of its rarity, standardized management for MRKH syndrome is unavailable. This study reviewed the management of the patients with MRKH syndrome in our institution. Methods: Using medical records, we retrospectively reviewed the surgical techniques, outcomes, postoperative management methods, and outpatient follow-up of 17 patients with MRKH syndrome in Keio University Hospital. Results: Of the 14 patients who requested vaginoplasty, 12 underwent surgery with Davydov’s modified procedure after the Frank method, and it took 17 months to 34 months (median two years) for the vaginal cavity to enlarge by 5–6 cm. The Frank method is a non-surgical dilation with instrumental stretching of the vaginal vestibular mucosa. Davydov’s procedure is a surgical vaginoplasty in which the vesicoureteral space is coated by the peritoneum. Although one patient lost 3800 mL of bleeding from the plexus vein and four needed to remove the prosthesis under anesthesia about one month after surgery, all patients achieved anatomic success with a vaginal cavity length of 6 cm or more and could have sexual intercourse with their sexual partners. However, two patients interrupted their preoperative hospital visits, and three were lost to follow-up postoperatively. Two of the three patients who did not accept vaginoplasty presented myoma at uterine trace and underwent myomectomy. Another one was scheduled for surgery through psychological support. Conclusions: Davydov’s modified procedure is effective, and dilating the vaginal cavity adequately using the Frank method before surgery is needed to ensure sufficient vaginal length with less perineum. During the operation, attention is required to care for the plexus vein. Comprehensive psychological support, providing appropriate information to the patient for mental maturity, and planning surgery according to their life stages are essential for successful treatment.

  • Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer

    Kitazawa S., Chiyoda T., Nakamura K., Sakai K., Yoshihama T., Nishio H., Kobayashi Y., Iwata T., Banno K., Yamagami W., Nishihara H., Aoki D.

    International Journal of Clinical Oncology （International Journal of Clinical Oncology)   2023

    ISSN  13419625

    　View Summary

    Background: Japan’s health insurance covers multigene panel testing. This study aimed to determine the potential availability and utility of gene panel testing clinically in gynecologic oncology. Methods: We analyzed the characteristics of patients with gynecologic cancer who underwent gene panel testing using FoundationOne® CDx or OncoGuide™ NCC Oncopanel between November 2019 and October 2022. Results: Out of 102 patients analyzed, 32, 18, 43, 8, and 1 had cervical, endometrial, ovarian cancers, sarcoma, and vaginal cancer, respectively. Druggable gene alteration was found in 70 patients (68.6%; 21 with cervical cancer, 15 with endometrial cancer, 28 with ovarian cancer, 5 with sarcoma, and 1 with other). The most common druggable gene alteration was PIK3CA mutation (n = 21), followed by PTEN mutation (n = 12) and high tumor mutation burden (TMB-H) (n = 11). TMB-H was detected in 5 patients with cervical cancer, 5 with endometrial cancer, and 1 with endometrial stromal sarcoma. Eleven patients (10.8%) received molecularly targeted therapy according to their gene aberrations. Gene panel testing was mostly performed when the second-line treatment was ineffective. Of all 102 patients, 60 did not have recommended treatment, and 15 died or had worsened conditions before obtaining the test results. Conclusion: Through multigene panel testing, although many patients had druggable gene alterations, 10.8% of them received the recommended treatment. TMB-H was mainly observed in cervical/endometrial cancer, suggesting its potential as a therapeutic biomarker of immune checkpoint inhibitors. Furthermore, patients’ prognosis and performance status should be considered before performing the test.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • Clinical Guidelines for Diagnosis and Management of Peutz-Jeghers Syndrome in Children and Adults.

    Yamamoto H, Sakamoto H, Kumagai H, Abe T, Ishiguro S, Uchida K, Kawasaki Y, Saida Y, Sano Y, Takeuchi Y, Tajima M, Nakajima T, Banno K, Funasawa Y, Hori S, Yamaguchi T, Yoshida T, Ishikawa H, Iwama T, Okazaki Y, Saito Y, Matsuura N, Mutoh M, Tomita N, Akiyama T, Yamamnoto S, Ishida H, Nakayama Y.

    Digestion    1 - 13 2024.04

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Graft Failure after Uterus Tansplantation in 16 Recipients: A Revew.

    Kisu I, Matsuda R, Shiraishi T, Hayashi R, Matoba Y, Tamate T, Banno K.

    Journal of Clinical Medicine 12 ( 5 ) 2032 2023.03

    Article, review, commentary, editorial, etc. (scientific journal), Last author

  • 子宮移植. -代理懐胎との関連を含めて-

    木須伊織、阪埜浩司.

    HORMONE FRONTIER IN GYNECOLOGY 29 ( 4 ) 273 - 281 2022.12

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work, Last author

  • Importance of comprehensive postoperative care among patients with Mayer- Rokitansky-Küster-Hauser syndrome undergoing vaginoplasy in Japan.

    Kisu I, Banno K, Aoki D.

    J Obstet Gynaecol Res 48 ( 12 ) 3338 - 3339 2022.12

    Article, review, commentary, editorial, etc. (scientific journal)

  • 生涯研修プログラム5．HBOC診療とRRSOならびにRRMの実践. HBOC診療とRRSOの実践.

    阪埜浩司

    日本産科婦人科学会誌 74 ( 11 ) 2241 - 2242 2022.11

    Rapid communication, short report, research note, etc. (scientific journal), Single Work, Lead author, Last author, Corresponding author

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • Analysis of residual ovarian cancer cells using the genetically engineered organoids model and human samples

    Kenta Masuda, Kouji Banno, Daisuke Aoki, Wataru Yamagami, Hideyuki Saya, Osamu Nagano

    第82回日本癌学会学術総会 (〒220-0012　神奈川県横浜市西区みなとみらい1-1-1　パシフィコ横浜) , 

    2023.09
    , 

    Symposium, workshop panel (public)

  • 子宮移植手術を想定した Cadaver Surgical Training の取組み

    木須 伊織、尾原 秀明、松原 健太郎、長谷川 康、山田 洋平、森田 伸也、高詰 佳史、今西 宜晶、久保田 義顕、白石 哲郎、松田 理沙、林 龍馬、 山上 亘、阪埜 浩司

    第59回日本移植学会総会 (〒606-8343 京都市左京区岡崎成勝寺町9番地の1　京都市勧業館 みやこめっせ) , 

    2023.09
    , 

    Oral presentation (general)

  • Identification of biomarkers associated to poor prognosis in high- grade serous carcinoma using novel mouse models

    Keiyo Imaeda, Kenta Masuda, Shimpei Nagai, Tomohiro Tamura, Eiji Sugihara, Juntaro Yamasaki, Yuji Otsuki, Hiroyuki Nobusue, Tatsuyuki Chiyoda, Yusuke Kobayashi, Kouji Banno, Daisuke Aoki, Wataru Yamagami, Hideyuki Saya, Osamu Nagano

    第82回日本癌学会学術総会 (〒220-0012　神奈川県横浜市西区みなとみらい1-1-1　パシフィコ横浜) , 

    2023.09
    , 

    Poster presentation

  • 再発子宮肉腫に対する薬物療法における新たなトレンド

    阪埜浩司

    悪性軟部腫瘍の治療戦略を考える会in群馬 (web) , 

    2023.09
    , 

    Public lecture, seminar, tutorial, course, or other speech

  • 複雑化する進行卵巣癌治療のBest Practiceを追求する〜患者のLifeを軸とした治療戦略〜

    阪埜浩司

    進行卵巣癌治療のBest Practiceを考える会〜手術を含む、多様な観点から〜 (web) , 

    2023.09
    , 

    Public lecture, seminar, tutorial, course, or other speech, 武田薬品工業株式会社

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • エピゲノム異常を標的とした子宮内膜癌の新たな診断・治療法の探索

    2016.04
    -
    2019.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • ラットにおける半導体レーザー手術装置に関する基礎的研究

    2009.12
    -
    Present

    Commissioned ｒesearch, No Setting

  • 子宮内膜症に関する創薬標的の探索および疾患モデルの構築

    2009.10
    -
    Present

    Joint research, No Setting

Page Top ▲

Awards 【 Display / hide 】

  • 平成25年度 日本医師会医学研究奨励賞

    BANNO KOUJI, 2013.11

  • 平成24年度　日本産科婦人科学会学術奨励賞

    BANNO KOUJI, 2012.12, 子宮体癌におけるジェネティクスとエピジェネティクス 〜子宮内膜の発癌とDNAミスマッチ修復遺伝子異常との関連を中心に〜

  • 平成23年度　医学部Best Teacher Award

    BANNO KOUJI, 2012.07

    Type of Award： Keio commendation etc.

  • 平成22年度　医学部Best Teacher Award

    BANNO KOUJI, 2011.06

    Type of Award： Keio commendation etc.

  • 平成21年度　医学部 Best Teacher Award

    BANNO KOUJI, 2010.03

    Type of Award： Keio commendation etc.

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • PATHOPHYSIOLOGICAL ISSUES IN ACUTE CARE

    2023

  • LECTURE SERIES, GYNECOLOGY

    2023

  • CLINICAL CLERKSHIP IN GYNECOLOGY

    2023

  • PATHOPHYSIOLOGICAL ISSUES IN ACUTE CARE

    2022

  • LECTURE SERIES, GYNECOLOGY

    2022

display all >>

Page Top ▲

Courses Previously Taught 【 Display / hide 】

  • 婦人科 臨床実習

    Keio University

    2015.04
    -
    2016.03
    , 

    Full academic year, Seminar, Lecturer outside of Keio, 5h, 100people

  • 大学院特別講義 臨床腫瘍学

    Keio University

    2015.04
    -
    2016.03
    , 

    Full academic year, Lecture, Within own ｆaculty, 30people

    家族性腫瘍

  • 婦人科学

    Keio University

    2015.04
    -
    2016.03
    , 

    Spring Semester, Lecture, Within own ｆaculty, 100people

  • 婦人科学 家族性腫瘍

    Keio University

    2014.04
    -
    2015.03
    , 

    Full academic year, Lecture, Within own ｆaculty

  • 婦人科学 臨床実習

    Keio University

    2014.04
    -
    2015.03
    , 

    Full academic year, Laboratory work/practical work/exercise, Within own ｆaculty

display all >>

Page Top ▲

Educational Activities and Special Notes 【 Display / hide 】

  • 大学院特別講義 臨床腫瘍学

    2015.11
    -
    Present

    , Special Affairs

  • 婦人科学

    2015.09
    -
    Present

    , Special Affairs

  • 婦人科臨床実習

    2015.05
    -
    2015.12

    , Special Affairs

Page Top ▲
 

Social Activities 【 Display / hide 】

  • 日本子宮移植研究会

    2014.03
    -
    Present

  • 日本学術会議

    2007.01
    -
    2008.04

  • 女性の健康基金

    2005
    -
    2006
Page Top ▲

Memberships in Academic Societies 【 Display / hide 】

  • 日本遺伝性腫瘍学会, 

    2009.01
    -
    Present

  • 日本医師会総合政策研究機構, 

    2007.01
    -
    2008.09

  • 日本癌治療学会, 

    2002
    -
    Present

  • 日本婦人科腫瘍学会, 

    2002
    -
    Present

  • 日本臨床細胞学会, 

    2002
    -
    Present

display all >>

Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2020.09
    -
    2022.08

    査読委員, 日本婦人科腫瘍学会

  • 2020.07
    -
    2022.06

    ガイドライン委員, 日本遺伝性腫瘍学会

  • 2020.07
    -
    2022.06

    作業部会委員, 日本遺伝性腫瘍学会

  • 2014.03
    -
    Present

    Director, 日本子宮移植研究会

  • 2009.01
    -
    Present

    Board of Councillors, 日本家族性腫瘍学会

display all >>

Page Top ▲